Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer. The Company is advancing [225Ac]-FPI-1434, its lead product candidate that combines the precision targeting of an antibody with the potency of alpha-particle emitting medical isotopes to specifically attack and eradicate cancer cells across multiple tumor types. It also operates Fast-Clear™, a linker technology platform that promotes the rapid excretion of medical isotopes that are not specifically bound to cancer cells.